1207993-83-6
Chemical Structure
Bozepinib
- CAS No.: 1207993-83-6
- Formula:C20H14Cl2N6O5S
- Molecular Weight:521.33
IUPAC Name: 3-(2,6-dichloro-9H-purin-9-yl)-1-((4-nitrophenyl)sulfonyl)-1,2,3,5-tetrahydrobenzo[e][1,4]oxazepine
InChIKey: ADWZQHLAYGEBHB-UHFFFAOYSA-N
SMILES: O=S(N1CC(OCC2=CC=CC=C21)N3C=NC4=C3N=C(N=C4Cl)Cl)(C5=CC=C(C=C5)[N+]([O-])=O)=O
Biological Activity: Bozepinib is an anticancer agent. Bozepinib induces Apoptosis, and inhibits the HER-2 signaling pathway as well as JNK and ERK kinases. Bozepinib induces the down-regulation of c-MYC, β-catenin and SOX2 proteins, and the up-regulation of GLI-3. Bozepinib can be used in the research of breast cancer and colon cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bozepinib | Bozepinib is an anticancer agent. Bozepinib induces Apoptosis, and inhibits the HER-2 signaling pathway as well as JNK and ERK kinases. Bozepinib induces the down-regulation of c-MYC, β-catenin and SOX2 proteins, and the up-regulation of GLI-3. Bozepinib can be used in the research of breast cancer and colon cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Morales F, et al. p-Nitrobenzenesulfonamides and their fluorescent dansylsulfonamides derived from N-alkylated o-(purine-methyl) anilines as novel antitumour agents[J]. RSC advances, 2015, 5(93): 76615-76619.
- [2]. Ramírez A, et al. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound. Oncotarget. 2014 Jun 15;5(11):3590-606. [Content Brief]
- [3]. Marchal JA, et al. Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence. Drug design, development and therapy. 2013;7:1301-13. [Content Brief]
